Form D · Biotechnology
Graviton BioScience Corp
New York, NY · CIK 0001847048
Offering snapshot reported Feb 14, 2024 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 14, 2024 | Initial | $24,999,996 | No comparison | 1 | SEC filing |
| Dec 4, 2023 | Initial | $24,999,998 | No comparison | 1 | SEC filing |
| Dec 4, 2023 | Initial | $39,819,496 | No comparison | 11 | SEC filing |
| Feb 19, 2021 | Initial | $3,500,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-505280
Source: Form D, filed Feb 14, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Philip Barach | Director |
| James Boylan | Director |
| Bihua Chen | Director |
| Richard Giroux | Director |
| Steven Gordon | Director, Executive |
| Jeremy Levin | Director |
| David Mac Millan | Director |
| Ran Nussbaum | Director |
| Stelios Papadopoulos | Director |
| Samuel D Waksal | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
125 West End Ave Suite 301
New York, NY, 10023
New York, NY, 10023